


CP-346086 dihydrate

Cat. No.:	HY-113955A
CAS No.:	1262769-98-1
Molecular Formula:	C ₂₆ H ₂₆ F ₃ N ₅ O ₃
Molecular Weight:	513.51
Target:	Microsomal Triglyceride Transfer Protein (MTP)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC ₅₀ of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo ^[1] .								
IC₅₀ & Target	IC ₅₀ : 2.0 nM (MTP) ^[1]								
In Vitro	<p>CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC₅₀ of 2.0 nM^[1].</p> <p>CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC₅₀=2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice^[1].</p> <p>CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats^[1].</p> <p>CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="341 1428 1510 1711"> <tr> <td>Animal Model:</td> <td>B6CBAF1J mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1, 2, 10, 20, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage once daily for 2 weeks</td> </tr> <tr> <td>Result:</td> <td>Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day.</td> </tr> </table>	Animal Model:	B6CBAF1J mice ^[1]	Dosage:	1, 2, 10, 20, 100 mg/kg	Administration:	Oral gavage once daily for 2 weeks	Result:	Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day.
Animal Model:	B6CBAF1J mice ^[1]								
Dosage:	1, 2, 10, 20, 100 mg/kg								
Administration:	Oral gavage once daily for 2 weeks								
Result:	Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day.								

REFERENCES

[1]. Chandler CE, et, al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003 Oct;44(10):1887-901.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA